428.75 -6.15(-1.41%)
Open Price (₹)
Prev. Close (₹)
Volume (No’s)
Market Cap (₹)
Low Price (₹)
High Price (₹)
OI(₹)
Market Cap(₹Cr.)
P/E (TTM)
Book value (₹)
Div Yield (%)
EPS (TTM)
Face Value (₹)
Key Level
Resistance 1
Resistance 2
Support 1
Support 2
Moving Average
30 Days
50 Days
100 Days
200 Days
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ Returns(%)
in 12 36 60 Months Ago
My investment would be worth₹ with a Loss of
Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018. The name of the Company has been changed to Cohance Lifesciences Limited w.e.f. May 7, 2025. Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors. The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Co...